Literature DB >> 17184637

Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease.

Whady Hueb1, Bernard J Gersh, Fernando Costa, Neuza Lopes, Paulo R Soares, Paulo Dutra, Fabio Jatene, Alexandre C Pereira, Aécio F T Góis, Sergio A Oliveira, José A F Ramires.   

Abstract

BACKGROUND: Diabetes mellitus is a major cause of coronary artery disease. Despite improvement in the management of patients with stable coronary artery disease, diabetes remains a major cause of increased morbidity and mortality. Although coronary artery bypass grafting surgery (CABG) and percutaneous coronary intervention are widely used, no conclusive evidence exists that either treatment modality is better than medical therapy alone for the treatment of stable single- or multivessel coronary disease in patients with diabetes.
METHODS: We compared medical therapy, percutaneous coronary intervention, and CABG in 499 diabetic patients (38.5%) and 799 nondiabetic patients (61.5%) with single- or multivessel coronary disease. The composite primary endpoint was cardiac-related death, Q-wave myocardial infarction, or refractory angina requiring revascularization.
RESULTS: We treated 1,298 patients with either CABG (n = 524), percutaneous coronary intervention (n = 378), or medical therapy (n = 396). More deaths occurred among patients with diabetes than among patients without diabetes, regardless of which option was used (p < 0.001). When treatment modalities were stratified according to the number of diseased vessels, CABG was shown to be more beneficial for patients with diabetes and multivessel disease than for patients with diabetes and single-vessel disease (p < 0.001). However, when stratified by treatment, patients with diabetes receiving medical therapy had a worse prognosis than patients with diabetes treated with CABG (p = 0.005).
CONCLUSIONS: All three therapeutic regimens resulted in high rates of cardiac-related deaths among patients with diabetes compared with patients without diabetes. Moreover, we observed better outcomes among patients with diabetes and multivessel coronary artery disease undergoing CABG regarding the primary endpoint at 5-year follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17184637     DOI: 10.1016/j.athoracsur.2006.08.050

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells.

Authors:  Kazuhide Ishikura; Hirofumi Misu; Masafumi Kumazaki; Hiroaki Takayama; Naoto Matsuzawa-Nagata; Natsumi Tajima; Keita Chikamoto; Fei Lan; Hitoshi Ando; Tsuguhito Ota; Masaru Sakurai; Yumie Takeshita; Kenichiro Kato; Akio Fujimura; Ken-Ichi Miyamoto; Yoshiro Saito; Satomi Kameo; Yasuo Okamoto; Yoh Takuwa; Kazuhiko Takahashi; Hiroyasu Kidoya; Nobuyuki Takakura; Shuichi Kaneko; Toshinari Takamura
Journal:  Diabetologia       Date:  2014-07-03       Impact factor: 10.122

2.  The association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study.

Authors:  Kimbach T Carpiuc; Deborah L Wingard; Donna Kritz-Silverstein; Elizabeth Barrett-Connor
Journal:  J Womens Health (Larchmt)       Date:  2010-08       Impact factor: 2.681

Review 3.  Conservative strategy for treatment of stable coronary artery disease.

Authors:  Paulo Cury Rezende; Thiago Luis Scudeler; Leandro Menezes Alves da Costa; Whady Hueb
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

4.  Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives.

Authors:  Ryo Naito; Takatoshi Kasai
Journal:  World J Cardiol       Date:  2015-03-26

5.  The role of revascularization versus medical therapy in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Brian J Page; Dmitriy Kireyev; William E Boden
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

6.  Disorder gene expression of extracellular matrix and adhesion molecules in saphenous vein conduits of diabetic patients.

Authors:  Yongxin Sun; Wenjun Ding; Qiang Wei; Wang Chun Sheng
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-14

7.  High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism.

Authors:  Federico Biscetti; Giuseppe Straface; Raimondo De Cristofaro; Stefano Lancellotti; Paola Rizzo; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Kensuke Egashira; Giulia De Angelis; Giovanni Ghirlanda; Andrea Flex
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

8.  Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery.

Authors:  Jorge Chiquie Borges; Neuza Lopes; Paulo R Soares; Aécio F T Góis; Noedir A Stolf; Sergio A Oliveira; Whady A Hueb; Jose A F Ramires
Journal:  J Cardiothorac Surg       Date:  2010-10-26       Impact factor: 1.637

9.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Authors:  Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

10.  Ephrin-B2-activated peripheral blood mononuclear cells from diabetic patients restore diabetes-induced impairment of postischemic neovascularization.

Authors:  Dong Broquères-You; Carole Leré-Déan; Tatiana Merkulova-Rainon; Chris S Mantsounga; David Allanic; Patricia Hainaud; Jean-Olivier Contrères; Yu Wang; José Vilar; Marie Virally; Jean-Jacques Mourad; Pierre-Jean Guillausseau; Jean-Sébastien Silvestre; Bernard I Lévy
Journal:  Diabetes       Date:  2012-05-17       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.